echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Latest Medical News > PI3K dual inhibitor!

    PI3K dual inhibitor!

    • Last Update: 2021-05-23
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    Source: Guanlan Pharmaceutical

    On April 19, CSPC announced that its subsidiary CSPC Zhongqi Pharmaceutical Technology (Shijiazhuang) Co.


    According to the announcement, Duensibu capsules are declared in accordance with the 5.


    According to public information, it is speculated that the new drug is Copiktra (duvelisib) introduced by CSPC from Verastem Oncology in September 2018.


    Duvelisib's approval in the United States for the treatment of FL is mainly based on a single-arm, multi-center phase 2 clinical trial.


    Follicular lymphoma is a common type of lymphoma and the most common type of indolent lymphoma.


    Note: This article aims to introduce the progress of medical and health research, not to recommend treatment options.


    Reference materials:

    [1]Voluntary Announcement-The National Medical Products Administration accepts the listing application of "Duensibu Capsules".


    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Related Articles

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.